Principal Investigator's Responsibilities

Health Sciences Institutional Review Board Health Sciences Institutional Review Board 190 Galena Hall Columbia, MO 65212 (mail distribution code Dc074.00) 573 882-3181 phone 573 884-4401 fax irb@missouri.edu

Principal Investigator's Responsibilities

1. General Responsibilities of Principal Investigators
   
   The principal investigator (PI) is responsible for personally conducting or supervising the conduct of human-subjects research and for protecting the rights, safety, and welfare of the subjects enrolled in the research. The PI must ensure that all human¬ subjects’ research is conducted in an ethical manner and in accordance with all federal, state, and local laws and regulations, institutional policies, and requirements or determinations of the HS IRB.
1. Supervising the conduct of human-subjects research
   
   The PI may delegate study-related tasks, but must adequately supervise study personnel to whom tasks are delegated. When supervising the conduct of human subject’s research, the PI must ensure that:
1. Study personnel are qualified by training and experience to perform study related tasks that have been delegated to them
2. Study personnel have an adequate understanding of the research
3. Study personnel follow the IRB-approved protocol, including the recruitment and consent procedures described in the protocol summary

The PI should have a plan for supervision and oversight of the research. The intensity of the supervision should take into consideration the study personnel conducting the research, the nature of the research, and the subject population.

When tasks are delegated by the investigator, the investigator is responsible for providing adequate supervision of those to whom tasks are delegated and the investigator is accountable for violations resulting from failure to adequately supervise the conduct of the study.

2. Protecting the rights, safety, and welfare of research subjects
   
   When protecting the rights, safety, and welfare of research subjects, the PI must ensure that:
1. S/he or other identified, qualified individual( s) provides study subjects with reasonable medical care for any adverse events, including clinically significant laboratory values, related to the research
2. S/he or another specific qualified individual is available to study subjects to answer questions or provide care during the conduct of the researchS/he and all research staff conducting the study adhere closely to the research plan, such as inclusion/exclusion criteria, safety assessments, safety monitoring and reporting of unanticipated problems, and procedures to protect privacy of subjects and confidentiality of identifiable data, in order to minimize risks to subjects.

The PI should not commence the research without adequate resources to protect subjects participating in the research and should stop the research if the resources necessary to protect subjects become unavailable. These resources might include research personnel, space, equipment, time, and availability of medical or psychological care for problems that arise during participation in the research.

2. More Specific Responsibilities of Principal Investigators
1. The PI must ensure that:
1. HS IRB approval is obtained prior to initiation of the research
2. The research is conducted in accordance with the HS IRB-approved protocol, including, when applicable, the approved recruitment and consent procedures
3. When informed consent is required, informed consent is obtained prior to the initiation of any study-related procedures
4. When written informed consent is required, informed consent is obtained and documented using the current HS IRB-approved research consent form
5. When drugs, biological products, and devices are being investigated or used, they are managed and controlled as required by institutional policy and, when applicable, FDA regulations 21 CRF 312 and 21 CFR 812
6. Changes to the HS IRB-approved protocol and/or the research consent form are not initiated without prospective HS IRB approval unless necessary to eliminate apparent immediate hazards to the subject
7. Unanticipated problems involving risks to subjects or others (including adverse events) are reported promptly to the HS IRB in accordance with HS IRB policy
8. When applicable, Data and Safety Monitoring Board/Data Monitoring Committee or other monitoring group reports are submitted promptly to the HS IRB for review
9. Continuing review is conducted prior to expiration of HS IRB approval in accordance with HS IRB policy
10. Should HS IRB approval lapse, research procedures, such as recruitment and enrollment of subjects, study procedures on currently enrolled subjects, review of health/medical records, collection of tissue or other samples, or analysis of data, are not conducted until the HS IRB re-approves the research or until special permission is obtained from the HS IRB to continue previously enrolled subjects because it is in their best interests to do so
11. When the research has been completed or is being closed out prior to completion, a final continuing review report is submitted to the HS IRB
12. Adequate and accurate research records are kept and retained as required by the HS IRB and, when applicable, by the sponsor or FDA
13. Research records are made available to the HS IRB, the sponsor, and when applicable, the Office for Human Research Protections (OHRP), and the Food and Drug Administration (FDA) upon request for monitoring and oversight of the research